The White House’s new AI strategy—namely President Trump’s July 23, 2025 “AI Action Plan” and executive orders—could affect healthcare in several key ways:
Regulatory rollback vs Biden’s safeguards
The Trump plan emphasizes deregulation and removing barriers to implementation—potentially accelerating adoption of AI tools in healthcare. In contrast, Biden’s 2023 Executive Order required robust oversight, including HHS oversight programs, safety reporting mechanisms, and inbox for clinical error reporting in partnership with Patient Safety Organizations. For more, click here
Quality Assurance and AI Assurance Policy
Biden’s Executive Order directed HHS to create an “AI assurance policy” to evaluate the performance of AI-driven healthcare tools in both pre-market and real-world settings. The Trump plan does not specifically emphasize such quality control frameworks. Read more here
Mitigating bias vs ideological neutrality mandates
Under Biden, AI systems in healthcare needed to comply with federal nondiscrimination laws, with HHS supporting providers and payers through compliance training, monitoring of biases, and issuing guidance in response to violations
The Trump plan includes a directive for federal procurement of AI tools to be “ideologically neutral,” which has stirred controversy. While minimizing ideological bias sounds neutral in theory, it may deprioritize equity-focused or culturally-aware designs. Critics fear these criteria could undermine protections for marginalized patient populations. Read more here
Incentives & grants
Both Biden’s and Trump’s strategies support AI innovation, but Biden’s plan prioritized health equity and researcher diversity through programs like NIH’s AIM‑AHEAD and other grantmaking toward equitable AI diagnostics and drug development.
Trump’s plan shifts focus more toward infrastructure expansion, including data center development and faster permitting, with fewer explicit healthcare-targeted research investments. It does promise broader exports of U.S. AI capabilities applied to healthcare among other sectors. Read more here
In short: Trump’s AI strategy could accelerate healthcare AI deployment—but at the price of scaling back the safety, equity, and oversight mechanisms built into Biden’s AI directives. That trade-off may reshape how AI is used in diagnostics, treatment, insurance, and patient care settings—potentially benefiting speed of innovation, but increasing risks to patient safety, bias, and health equity.
The IDN Directory provides insights into the supply chains for the biggest health systems in the country to give manufacturer reps, distribution reps, and national accounts managers a quick, accurate view of what’s going on with their customers - right now. Contact us at demo@idndirectory.com to schedule a demo today.
